BACKGROUND AND OBJECTIVE: Vestibular dysfunction commonly leads to - often severe - vertigo symptoms. The objective of this study was to compare the antivertiginous efficacy and tolerability of a fixed combination of cinnarizine/dimenhydrinate with those of betahistine in patients with acute vertigo due to vestibular disorders. METHODS: Sixty-six patients experiencing acute vertigo attacks participated in this prospective, double-blind, three-centre, comparative study. Patients who assessed at least one vertigo symptom as being of medium intensity (> or =2) on a 5-point visual analogue scale (VAS; from 0 = no symptoms to 4 = very severe symptoms) were randomly allocated to treatment with the fixed combination of cinnarizine 20 mg and dimenhydrinate 40 mg three times daily or betahistine 12 mg three times daily for 4 weeks. The primary efficacy endpoint was change in mean vertigo score, as determined by patients' assessments of 12 individual vertigo symptoms on the 5-point VAS after 4 weeks of treatment. RESULTS: Treatment with the fixed combination led to significantly greater improvements in mean vertigo scores than the reference therapy betahistine after 4 weeks of therapy (p = 0.013). The differences were clinically relevant, based on the Mann-Whitney estimator. Furthermore, the incidence of vertigo-associated vegetative symptoms was significantly reduced after 1 (p = 0.004) and 4 weeks (p = 0.023) in the fixed-combination group relative to the betahistine group. Three patients, all of them in the betahistine group, reported adverse events, none of which was considered serious. Almost all patients (n = 62) rated the tolerabilities of both medications as very good or good. CONCLUSION: The fixed combination of cinnarizine/dimenhydrinate was shown to be an effective and very well tolerated treatment option for patients with acute vertigo due to vestibular disorders. The combination proved to be significantly more efficient in reducing vertigo and associated vegetative symptoms than betahistine in such patients.

Ear Nose and Throat Department Faculty Hospital Královské Vinohrady 3rd Medical Faculty Charles University Prague Czech Republic

See more in PubMed

Naunyn Schmiedebergs Arch Pharmacol. 2005 Jun;371(6):441-8 PubMed

Acta Otorhinolaryngol Belg. 1985;39(6):924-32 PubMed

J Pharmacol Exp Ther. 1971 Mar;176(3):718-24 PubMed

Arch Otolaryngol. 1949 Jun;49(6):594-608 PubMed

Clin Drug Investig. 2005;25(6):377-89 PubMed

Clin Ther. 2007 Jan;29(1):84-98 PubMed

Clin Ther. 2004 Jun;26(6):866-77 PubMed

Int Tinnitus J. 1999;5(1):60-2 PubMed

Br J Gen Pract. 1998 Dec;48(437):1828-32 PubMed

Int J Clin Pharmacol Ther. 2004 Apr;42(4):218-31 PubMed

Acta Otolaryngol Suppl. 1991;479:24-8 PubMed

Naunyn Schmiedebergs Arch Pharmacol. 2004 Jun;369(6):570-5 PubMed

Prog Brain Res. 1989;80:411-8; discussion 395-7 PubMed

Otolaryngol Clin North Am. 1975 Jun;8(2):455-66 PubMed

CNS Drugs. 2003;17(2):85-100 PubMed

J Neurol Neurosurg Psychiatry. 2004 Dec;75 Suppl 4:iv45-52 PubMed

Int Tinnitus J. 2002;8(2):115-23 PubMed

Acta Otolaryngol Suppl. 1972;305:29-47 PubMed

Int J Clin Pharmacol Ther. 2003 Apr;41(4):171-81 PubMed

Laryngorhinootologie. 1993 Jun;72(6):311-5 PubMed

Int J Technol Assess Health Care. 1988;4(4):637-42 PubMed

Efficacy and Safety of a Fixed Combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg vs Betahistine Dihydrochloride 16 mg in Patients with Peripheral Vestibular Vertigo: A Prospective, Multinational, Multicenter, Double-Blind, Randomized, Non-inferiority Clinical Trial

Comparison of cinnarizine/dimenhydrinate fixed combination with the respective monotherapies for vertigo of various origins: a randomized, double-blind, active-controlled, multicentre study